Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Highly targeted medication for AML

Andrew Wei • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia

There have been large strides in the treatment of leukemia; however, current methods lack specificity. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Andrew Wei, MBBS, PhD, FRACP, FRCPA from Alfred Hospital and Monash University, Melbourne, Australia discusses the use of targeted medication to inhibit anti-apoptotic proteins and how this could reduce toxicity.

More from Andrew Wei

TP53 mutation in AML
Andrew Wei et al. • 4 Sep 2023
6:41
Clinical trials aiming to reduce the toxicity of novel agents in AML
Andrew Wei • 9 Dec 2022
6:14
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up
Andrew Wei • 15 Dec 2021
1:32
AML data at ASH 2021 and implications on clinical practice
Andrew Wei • 15 Dec 2021

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals